- $426.65m
- $440.45m
- $1.82m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.45 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 234.81 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -60.96% | ||
| Return on Equity | -178% | ||
| Operating Margin | -17549.97% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 7.3 | 23.85 | 25.99 | 0.16 | 1.82 | 3 | 2.38 | 50.41% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cibus, Inc. is an agricultural technology company that uses gene editing technologies to develop plant traits in seeds. Its business is the development of plant traits that help address specific productivity or yield challenges in farming, such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate. It is also engaged in developing, certain alternative plant-based oils or bio-based fermentation products. Its technology is its gene editing platform called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits, four of which are applicable to multiple crops. These traits are PSR in Canola and HT1 and HT3 in rice. In addition, it also has two advanced traits for Sclerotinia resistance and another novel broadleaf HT trait, HT2.
Directors
- Yves Ribeill NEC (61)
- Michael Carr PRE (53)
- William Koschak CFO (52)
- Gerry Nuovo SVP
- Travis Frey CTO (43)
- Debra Frimerman GCN (41)
- Laurent Arthaud DRC (58)
- Philippe Dumont IND (69)
- Jonathan Fassberg IND (55)
- Anna Kozicz-stankiewicz IND (46)
- Kimberly Nelson IND (53)
- Christopher Neugent IND (60)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 8th, 2010
- Public Since
- July 20th, 2017
- No. of Shareholders
- 482
- No. of Employees
- 183
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 24,132,009
- Address
- 6455 Nancy Ridge Drive, SAN DIEGO, 92121
- Web
- https://calyxt.com/
- Phone
- +1 8584500008
- Contact
- Kimberly Minarovich
- Auditors
- Ernst & Young LLP
Upcoming Events for CBUS
Calyxt Inc Annual Shareholders Meeting
Q2 2024 Cibus Inc Earnings Release
Similar to CBUS
Accelerate Diagnostics
NASDAQ Capital Market
Acutus Medical
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the Cibus share price?
As of Today at 19:05 UTC, shares in Cibus are trading at $17.68. This share price information is delayed by 15 minutes.
How has the Cibus share price performed this year?
Shares in Cibus last closed at $17.68 and the price had moved by +483.31% over the past 365 days. In terms of relative price strength the Cibus share price has outperformed the S&P500 Index by +371.07% over the past year.
What are the analyst and broker recommendations for Cibus?
The overall consensus recommendation for Cibus is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cibus dividend yield?
Cibus does not currently pay a dividend.
Does Cibus pay a dividend?
Cibus does not currently pay a dividend.
When does Cibus next pay dividends?
Cibus does not currently pay a dividend.
How do I buy Cibus shares?
To buy shares in Cibus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cibus?
As of the previous close price of $17.68, shares in Cibus had a market capitalisation of $426.65m.
Where are Cibus shares listed?
Here are the trading details for Cibus:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CBUS
What kind of share is Cibus?
Based on an overall assessment of its quality, value and momentum Cibus is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cibus share price forecast for 2024?
The analyst consensus target price for shares in Cibus is $22.00. That is 24.43% above the last closing price of $17.68.
Analysts covering Cibus currently have a consensus Earnings Per Share (EPS) forecast of -$3.37 for the next financial year.
What is the trend in the Cibus share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cibus. Over the past six months, its share price has underperformed the S&P500 Index by -13.46%.
As of the last closing price of $17.68, shares in Cibus were trading +3.56% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cibus PE Ratio?
The Cibus PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $17.68.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cibus?
Cibus' management team is headed by:
- Yves Ribeill - NEC
- Michael Carr - PRE
- William Koschak - CFO
- Gerry Nuovo - SVP
- Travis Frey - CTO
- Debra Frimerman - GCN
- Laurent Arthaud - DRC
- Philippe Dumont - IND
- Jonathan Fassberg - IND
- Anna Kozicz-stankiewicz - IND
- Kimberly Nelson - IND
- Christopher Neugent - IND